Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cidara Therapeutics (CDTX) Gains from Investment Securities: 2019-2025

Historic Gains from Investment Securities for Cidara Therapeutics (CDTX) over the last 1 years, with Mar 2025 value amounting to $50,000.

  • Cidara Therapeutics' Gains from Investment Securities changed negligibly% to $50,000 in Q1 2025 from the same period last year, while for Mar 2025 it was $276,000, marking a year-over-year decrease of 92.92%. This contributed to the annual value of $276,000 for FY2024, which is 92.83% down from last year.
  • Per Cidara Therapeutics' latest filing, its Gains from Investment Securities stood at $50,000 for Q1 2025, which was down 34.21% from $76,000 recorded in Q4 2024.
  • In the past 5 years, Cidara Therapeutics' Gains from Investment Securities ranged from a high of $3.8 million in Q2 2023 and a low of $50,000 during Q1 2024.
  • Moreover, its 3-year median value for Gains from Investment Securities was $75,000 (2024), whereas its average is $695,500.
  • Data for Cidara Therapeutics' Gains from Investment Securities shows a maximum YoY slumped of 98.05% (in 2024) over the last 5 years.
  • Cidara Therapeutics' Gains from Investment Securities (Quarterly) stood at $3.8 million in 2023, then tumbled by 98.05% to $76,000 in 2024, then remained steady at $50,000 in 2025.
  • Its Gains from Investment Securities was $50,000 in Q1 2025, compared to $76,000 in Q4 2024 and $75,000 in Q3 2024.